BPC-157 vs Pentadeca Arginate
Side-by-side comparison of BPC-157, Pentadeca Arginate — mechanism, dosing, half-life, side effects, and research status.
| Attribute | BPC-157 Body Protection Compound-157 Recovery | Pentadeca Arginate Pentadeca Arginate (PDA) — BPC-157 Arginine Variant Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Gastric Pentadecapeptide | Pentadecapeptide Arginine Analogue |
| Amino acids | 15 | 15 |
| Molecular weight | 1,419.5 Da | 1,476.6 Da |
| Half-life | ~4 hrs (SC) | ~4–6 hrs (estimated) |
| Route(s) | Subcutaneous, Intramuscular, Oral (research only) | Subcutaneous, Intramuscular, Oral (research) |
| Mechanism & Research | ||
| Primary mechanism | BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o… | PDA shares BPC-157's primary mechanism of action: nitric oxide (NO) synthase upregulation, VEGFR2-mediated angiogenesis, and connective tissue repair signalling. The arginine modification may further amplify NO pathway a… |
| Research status | Research Compound | Research Compound |
| Evidence summary | The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e… | PDA is a newer research compound with a smaller published evidence base than BPC-157. Most researchers extrapolate from BPC-157's extensive preclinical data given the structural and mechanistic similarity. Direct compara… |
| Protocol & Dosing | ||
| Typical dose | 200–500 mcg per injection | 200–500 mcg per injection |
| Frequency | Once or twice daily | Once or twice daily |
| Duration | 4–12 weeks | 4–12 weeks |
| Timing | Near injury site when possible | Near injury site when possible; any time |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S0) | Prohibited (WADA S0) |
| Deeper reading | ||
| Related peptides | TB-500, GHK-Cu, KPV, Pentadeca Arginate | BPC-157, TB-500, GHK-Cu |
| Full profile | Read full BPC-157 profile → | Read full Pentadeca Arginate profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.